Schnieders Capital Management LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

Key Points

• Schnieders Capital Management LLC increased its stock position in Pfizer by 161.2% during the first quarter, owning a total of 59,806 shares worth approximately $1.5 million.
• Several hedge funds, including Brighton Jones LLC, have also significantly raised their stakes in Pfizer, with Brighton Jones increasing its position by 1,282.4% in the fourth quarter.
• Pfizer recently announced a quarterly dividend of $0.43 per share, resulting in a 7.0% dividend yield, despite a high dividend payout ratio of 124.64%.

Schnieders Capital Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 161.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 59,806 shares of the biopharmaceutical company's stock after purchasing an additional 36,910 shares during the period. Schnieders Capital Management LLC's holdings in Pfizer were worth $1,515,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PFE. Bessemer Group Inc. grew its stake in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its stake in shares of Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer during the first quarter worth about $8,283,000. Alta Advisers Ltd raised its position in shares of Pfizer by 69.6% in the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after purchasing an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC boosted its stake in Pfizer by 8.7% in the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after purchasing an additional 10,051 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Bank of America lifted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday. Redburn Atlantic cut their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group lifted their target price on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Berenberg Bank cut their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $28.44.

Pfizer Price Performance

Pfizer stock traded up $0.32 during midday trading on Thursday, reaching $24.25. The company had a trading volume of 45,468,611 shares, compared to its average volume of 46,190,364. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.96. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a market capitalization of $137.85 billion, a P/E ratio of 12.90, a P/E/G ratio of 0.87 and a beta of 0.52. The firm's fifty day simple moving average is $24.42 and its 200-day simple moving average is $24.52.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the business posted $0.60 earnings per share. The business's quarterly revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.